Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJO-087 vs. Cyclosporine 0.05% in Dry Eye Disease
NCT05245604Phase 3Unknown
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine 2% ophthalmic solution in dry eye syndrome (DED), sponsored by Taejoon Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT05245604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245604.